Description

Disclaimer: This is a research chemical only. It’s not a medication, and it’s not approved for human or animal use outside of authorized studies

CJC-1295 without DAC (Drug Affinity Complex) is a tetrasubstituted synthetic analog of growth hormone–releasing hormone (GHRH), engineered to enhance stability while preserving a short biological half-life. Unlike the DAC-modified form, this version does not bind to serum albumin, which allows for rapid clearance and a pharmacokinetic profile that more closely reflects endogenous, pulsatile GHRH secretion.

Researchers frequently use CJC-1295 (no DAC) to study the acute regulation of growth hormone (GH) secretion and its downstream effects on the GH–IGF-1 axis. Its transient activity enables controlled modeling of GH bursts in experimental systems, making it an important tool for evaluating short-term metabolic signaling, protein synthesis, and tissue repair mechanisms.

In vitro and preclinical studies often examine CJC-1295 (no DAC) both independently and in combination with growth hormone–releasing peptides (GHRPs) such as Ipamorelin, to better understand synergistic mechanisms of GH release. Key research applications include investigations into muscle hypertrophy, glucose metabolism, lipolysis, and endocrine feedback loops under tightly timed experimental conditions.

By offering precise control over secretion windows, CJC-1295 (no DAC) allows researchers to differentiate between acute and chronic GH signaling effects—an essential distinction in metabolic and regenerative biology.

The absence of DAC offers tighter experimental control over secretion windows and pharmacokinetics. Researchers study it for how it helps trigger natural pulses of growth hormone release — the kind your body does during deep sleep or after exercise. It’s often studied together with other compounds (like GHRPs) to explore how they may work together to boost natural Growth Hormone pathways.